
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
Novotech has released its 'Asia-Pacific Industry Highlights 2019-2020.’ The report says the region has had a record year by number of studies, experienced world-class sites and investigators, and patient enrollment.
For more of the report’s findings, click







